3rd Quarter - Report
WINNING STRATEGIES WASHINGTON for KALEO
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707; H.R. 3680 provisions related to Nalaxone; S. 2256 provisions related to Nalaxone
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARL CHIDLOW | — |
| MICHAEL A MEROLA | — |
| DONNA MULLINS | — |
| CHARLA PENN | — |
| CHELSEY PENROD HICKMAN | — |
| ROBERT ZUCKER | — |
Health Issues HCR
Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707; H.R. 3680 provisions related to Nalaxone; S. 2256 provisions related to Nalaxone
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARL CHIDLOW | — |
| MICHAEL A MEROLA | — |
| DONNA MULLINS | — |
| CHARLA PENN | — |
| CHELSEY PENROD HICKMAN | — |
| ROBERT ZUCKER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.